Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero

SAB Jan26

Published 23 January 2026
Categorized as -others, 2026, 2026, Press release

Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse

medRxiv 2026

Published 9 January 2026
Categorized as 2026, Myvac, Press release, TG4050

Transgene to Participate in Upcoming Investor Meetings

investors 2026

Published 17 December 2025
Categorized as 2025, Press release

Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets

resume 2025

Published 27 November 2025
Categorized as 2025, Press release

Transgene Announces the Success of Its Capital Increase

Results 2025

Published 26 November 2025
Categorized as 2025, dates, dates, Press release, TG6002

Announces the Temporary Suspension of Trading of its Shares on Euronext Paris

Suspension 2025

Published 25 November 2025
Categorized as 2025, Press release

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines

ESMO AI 2026

Published 6 November 2025
Categorized as 2025, Myvac, Press release, TG4050

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

ESMO Poster

Published 20 October 2025
Categorized as 2025, BT-001, Press release

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025

ESMO Abstract

Published 13 October 2025
Categorized as 2025, BT-001, Press release

Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025

Title SITC

Published 3 October 2025
Categorized as 2025, Myvac, Press release, TG4050

Posts pagination

Newer posts Page 1 … Page 3 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu